You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Eli Lilly raised full-year 2026 revenue guidance to $91 and $92 billion, with non-GAAP earnings per share of $35 to $36. Retatrutide reduced A1C by 2.2% and delivered 20 to 21 percent weight loss versus semaglutide.
ELI LILLY AND COMPANY reported revenue of 67,170 and net income of 20,942 for the nine months ended September 30, 2026. The FDA approved orforglipron for obesity.
Eli Lilly and Company reported Q3 2026 revenue of $24.4 billion, up 39%, and reported EPS of $7.22, up 16%. It raised full-year revenue guidance to $91.0 to $92.0 billion and updated non-GAAP EPS guidance to $35.00 to $36.00.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Lilly delivered 39% Q3 revenue growth, higher EPS and margins, raised revenue and performance-margin guidance, and reported broad Mounjaro/Zepbound and newest-product growth alongside regulatory and pipeline advances and strong Medicare Bridge uptake. Pricing declines, nonrecurring benefits, acquired IPR&D charges, adverse-event discontinuations, and expected 2027 net-price pressure remained material offsets.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LLY
this stock
ELI LILLY & Co
|
$1.36T | +34.3% | +44.7% | 46.9 | 0.8% |
|
JNJ
Johnson & Johnson
|
$687.89B | +38.1% | +6.0% | 43.4 | 0.7% |
|
ABBV
AbbVie Inc.
|
$521.50B | +29.1% | +8.6% | 50.8 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$364.26B | +40.4% | +1.3% | 152.3 | 1.1% |
|
NVS
Novartis AG
|
$303.12B | +16.4% | — | — | 0.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Eli Lilly and Company reported Q3 2026 revenue of $24.4 billion, up 39%, and reported EPS of $7.22, up 16%. It raised full-year revenue guidance to $91.0 to $92.0 billion and updated non-GAAP EPS guidance to $35.00 to $36.00.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LLY | +6.6% | +14.8% | +35.6% | +1.8% | +34.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +4.0% | +16.0% | +35.1% | +2.0% | +23.7% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
